ELI LILLY AND COMPANY Other Revenue, Net (Deprecated 2018-01-31)
ELI LILLY AND COMPANY (LLY) reported Other Revenue, Net (Deprecated 2018-01-31) of $358.50 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Income Statement › Other Income
us-gaap:OtherSalesRevenueNet · last filed 2018-04-27
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $358.50M, a 49.13% increase year-over-year.
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $330.80M, a 46.11% increase year-over-year.
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $334.20M, a 54.36% increase year-over-year.
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $294.50M, a 41.25% increase year-over-year.
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2017 was $1.20B, a 43.92% increase from fiscal 2016.
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $833.70M, a 3.17% increase from fiscal 2015.
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $808.10M, a 2.50% increase from fiscal 2014.
- ELI LILLY AND COMPANY other revenue, net (deprecated 2018-01-31) for fiscal 2014 was $788.40M, a 11.43% increase from fiscal 2013.
| Period end | Other Revenue, Net (Deprecated 2018-01-31) 3 month | Other Revenue, Net (Deprecated 2018-01-31) 6 month | Other Revenue, Net (Deprecated 2018-01-31) 9 month | Other Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $358.50M 10-Q · filed 2018-04-27 | $689.30M derived: sum of 2 quarters · filed 2018-04-27 | $1.02B derived: sum of 3 quarters · filed 2018-04-27 | $1.32B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-12-31 | $330.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $665.00M derived: sum of 2 quarters · filed 2018-02-20 | $959.50M derived: sum of 3 quarters · filed 2018-02-20 | $1.20B 10-K · filed 2018-02-20 |
| 2017-09-30 | $334.20M 10-Q · filed 2017-10-27 | $628.70M derived: sum of 2 quarters · filed 2017-10-27 | $869.10M 10-Q · filed 2017-10-27 | $1.10B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-06-30 | $294.50M 10-Q · filed 2017-07-28 | $534.90M 10-Q · filed 2017-07-28 | $761.30M derived: sum of 3 quarters · filed 2018-04-27 | $977.80M derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-03-31 | $240.40M 10-Q · filed 2018-04-27 | $466.80M derived: sum of 2 quarters · filed 2018-04-27 | $683.30M derived: sum of 3 quarters · filed 2018-04-27 | $891.80M derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $226.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $442.90M derived: sum of 2 quarters · filed 2018-02-20 | $651.40M derived: sum of 3 quarters · filed 2018-02-20 | $833.70M 10-K · filed 2018-02-20 |
| 2016-09-30 | $216.50M 10-Q · filed 2017-10-27 | $425.00M derived: sum of 2 quarters · filed 2017-10-27 | $607.30M 10-Q · filed 2017-10-27 | $770.70M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | $208.50M 10-Q · filed 2017-07-28 | $390.80M 10-Q · filed 2017-07-28 | $554.20M derived: sum of 3 quarters · filed 2018-02-20 | $769.40M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | $182.30M 10-Q · filed 2017-05-01 | $345.70M derived: sum of 2 quarters · filed 2018-02-20 | $560.90M derived: sum of 3 quarters · filed 2018-02-20 | $794.30M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $163.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $378.60M derived: sum of 2 quarters · filed 2018-02-20 | $612.00M derived: sum of 3 quarters · filed 2018-02-20 | $808.10M 10-K · filed 2018-02-20 |
| 2015-09-30 | $215.20M 10-Q · filed 2016-10-28 | $448.60M derived: sum of 2 quarters · filed 2016-10-28 | $644.70M 10-Q · filed 2016-10-28 | $839.20M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $233.40M 10-Q · filed 2016-07-28 | $429.50M 10-Q · filed 2016-07-28 | $624.00M derived: sum of 3 quarters · filed 2017-02-21 | $828.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $196.10M 10-Q · filed 2016-04-29 | $390.60M derived: sum of 2 quarters · filed 2017-02-21 | $594.60M derived: sum of 3 quarters · filed 2017-02-21 | $803.30M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $194.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $398.50M derived: sum of 2 quarters · filed 2017-02-21 | $607.20M derived: sum of 3 quarters · filed 2017-02-21 | $788.40M 10-K · filed 2017-02-21 |
| 2014-09-30 | $204.00M 10-Q · filed 2015-10-30 | $412.70M derived: sum of 2 quarters · filed 2015-10-30 | $593.90M 10-Q · filed 2015-10-30 | $794.70M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | $208.70M 10-Q · filed 2015-07-30 | $389.90M 10-Q · filed 2015-07-30 | $590.70M derived: sum of 3 quarters · filed 2016-02-19 | $774.10M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | $181.20M 10-Q · filed 2015-04-30 | $382.00M derived: sum of 2 quarters · filed 2016-02-19 | $565.40M derived: sum of 3 quarters · filed 2016-02-19 | $735.20M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $200.80M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $384.20M derived: sum of 2 quarters · filed 2016-02-19 | $554.00M derived: sum of 3 quarters · filed 2016-02-19 | $707.50M 10-K · filed 2016-02-19 |
| 2013-09-30 | $183.40M 10-Q · filed 2014-10-29 | $353.20M derived: sum of 2 quarters · filed 2014-10-29 | $506.70M 10-Q · filed 2014-10-29 | $664.20M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $169.80M 10-Q · filed 2014-07-28 | $323.30M 10-Q · filed 2014-07-28 | $480.80M derived: sum of 3 quarters · filed 2015-02-19 | $622.90M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $153.50M 10-Q · filed 2014-04-28 | $311.00M derived: sum of 2 quarters · filed 2015-02-19 | $453.10M derived: sum of 3 quarters · filed 2015-02-19 | $598.30M derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $157.50M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $299.60M derived: sum of 2 quarters · filed 2015-02-19 | $444.80M derived: sum of 3 quarters · filed 2015-02-19 | $633.00M 10-K · filed 2015-02-19 |
| 2012-09-30 | $142.10M 10-Q · filed 2013-10-30 | $287.30M derived: sum of 2 quarters · filed 2013-10-30 | $475.50M 10-Q · filed 2013-10-30 | $665.40M derived: sum of 4 quarters · filed 2014-02-19 |
| 2012-06-30 | $145.20M 10-Q · filed 2013-07-26 | $333.40M 10-Q · filed 2013-07-26 | $523.30M derived: sum of 3 quarters · filed 2014-02-19 | $699.50M derived: sum of 4 quarters · filed 2014-02-19 |
| 2012-03-31 | $188.20M 10-Q · filed 2013-04-26 | $378.10M derived: sum of 2 quarters · filed 2014-02-19 | $554.30M derived: sum of 3 quarters · filed 2014-02-19 | $720.60M derived: sum of 4 quarters · filed 2014-02-19 |
| 2011-12-31 | $189.90M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $366.10M derived: sum of 2 quarters · filed 2014-02-19 | $532.40M derived: sum of 3 quarters · filed 2014-02-19 | $681.70M 10-K · filed 2014-02-19 |
| 2011-09-30 | $176.20M 10-Q · filed 2012-10-26 | $342.50M derived: sum of 2 quarters · filed 2012-10-26 | $491.80M 10-Q · filed 2012-10-26 | $645.20M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $166.30M 10-Q · filed 2012-07-27 | $315.60M 10-Q · filed 2012-07-27 | $469.00M derived: sum of 3 quarters · filed 2013-02-21 | $637.00M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $149.30M 10-Q · filed 2012-04-30 | $302.70M derived: sum of 2 quarters · filed 2013-02-21 | $470.70M derived: sum of 3 quarters · filed 2013-02-21 | $630.10M derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | $153.40M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $321.40M derived: sum of 2 quarters · filed 2013-02-21 | $480.80M derived: sum of 3 quarters · filed 2013-02-21 | $633.80M 10-K · filed 2013-02-21 |
| 2010-09-30 | $168.00M 10-Q · filed 2011-10-28 | $327.40M derived: sum of 2 quarters · filed 2011-10-28 | $480.40M 10-Q · filed 2011-10-28 | $633.70M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-06-30 | $159.40M 10-Q · filed 2011-07-29 | $312.40M 10-Q · filed 2011-07-29 | $465.70M derived: sum of 3 quarters · filed 2012-02-24 | $642.20M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-03-31 | $153.00M 10-Q · filed 2011-04-29 | $306.30M derived: sum of 2 quarters · filed 2012-02-24 | $482.80M derived: sum of 3 quarters · filed 2012-02-24 | $662.30M derived: sum of 4 quarters · filed 2012-02-24 |
| 2009-12-31 | $153.30M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $329.80M derived: sum of 2 quarters · filed 2012-02-24 | $509.30M derived: sum of 3 quarters · filed 2012-02-24 | $664.50M 10-K · filed 2012-02-24 |
| 2009-09-30 | $176.50M 10-Q · filed 2010-10-29 | $356.00M derived: sum of 2 quarters · filed 2010-10-29 | $511.20M 10-Q · filed 2010-10-29 | |
| 2009-06-30 | $179.50M 10-Q/A · filed 2010-08-02 | $334.70M 10-Q/A · filed 2010-08-02 | ||
| 2008-12-31 | $114.20M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-22 | $231.30M derived: sum of 2 quarters · filed 2011-02-22 | $347.90M derived: sum of 3 quarters · filed 2011-02-22 | $446.10M 10-K · filed 2011-02-22 |
| 2008-09-30 | $117.10M 10-Q · filed 2009-10-30 | $233.70M derived: sum of 2 quarters · filed 2009-10-30 | $331.90M 10-Q · filed 2009-10-30 | |
| 2008-06-30 | $116.60M 10-Q · filed 2009-07-31 | $214.80M 10-Q · filed 2009-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |